Lazard Asset Management
XERS icon

Lazard Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Lazard Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,182
Closed -$61K – 2557
2025
Q1 		$61K Sell
11,182
-205,511
-95% -$830K ﹤0.01% 1952
2024
Q4 		$734K Sell
216,693
-161,646
-43% -$520K ﹤0.01% 1255
2024
Q3 		$1.08M Sell
378,339
-257,905
-41% -$662K ﹤0.01% 1053
2024
Q2 		$1.43M Buy
636,244
+215,757
+51% +$435K ﹤0.01% 900
2024
Q1 		$929K Buy
420,487
+16,674
+4% +$43.1K ﹤0.01% 936
2023
Q4 		$948K Buy
403,813
+88,326
+28% +$163K ﹤0.01% 965
2023
Q3 		$586K Buy
315,487
+190,049
+152% +$435K ﹤0.01% 1109
2023
Q2 		$328K Sell
125,438
-164,012
-57% -$418K ﹤0.01% 1219
2023
Q1 		$471K Sell
289,450
-56,932
-16% -$71.3K ﹤0.01% 1118
2022
Q4 		$460K Sell
346,382
-61,227
-15% -$86.4K ﹤0.01% 1141
2022
Q3 		$635K Sell
407,609
-116,685
-22% -$193K ﹤0.01% 1059
2022
Q2 		$807K Sell
524,294
-1,828,305
-78% -$3.86M ﹤0.01% 1025
2022
Q1 		$6.02M Sell
2,352,599
-128,076
-5% -$313K 0.01% 729
2021
Q4 		$7.27M Buy
2,480,675
+2,330,568
+1,553% +$5.03M 0.01% 711
2021
Q3 		$367K Buy
150,107
+137,558
+1,096% +$399K ﹤0.01% 1215
2021
Q2 		$51K Sell
12,549
-67,948
-84% -$259K ﹤0.01% 1596
2021
Q1 		$363K Sell
80,497
-16,097
-17% -$86.8K ﹤0.01% 1026
2020
Q4 		$475K Buy
96,594
+68,194
+240% +$341K ﹤0.01% 984
2020
Q3 		$168K Buy
+28,400
New +$114K ﹤0.01% 978

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lazard Asset Management's XERS Position: Q2 2025 in Review

Lazard Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2025, closing a stake of 11,182 shares — an estimated $61K sold.

Lazard Asset Management first reported a position in XERS in Q3 2020 and held it in 19 quarters. The position peaked at $7.27M in Q4 2021. 200 funds tracked by Wall St. Rank hold XERS as of Q2 2025.

  • Lazard Asset Management reported no remaining Xeris Biopharma Holdings position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 11,182 Xeris Biopharma Holdings shares in Q2 2025, an estimated $61K.
  • Lazard Asset Management first reported a position in Xeris Biopharma Holdings in Q3 2020 and held it in 19 quarters.
  • Lazard Asset Management's Xeris Biopharma Holdings position peaked at $7.27M in Q4 2021.
  • 200 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.